{"id":41526,"date":"2025-09-16T15:32:47","date_gmt":"2025-09-16T07:32:47","guid":{"rendered":"https:\/\/flcube.com\/?p=41526"},"modified":"2025-09-16T15:32:48","modified_gmt":"2025-09-16T07:32:48","slug":"rona-therapeutics-rn3161-sirna-targets-inhbe-submits-australian-trial-application","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41526","title":{"rendered":"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application"},"content":{"rendered":"\n<p><strong>Shanghai\u2011based Rona Therapeutics Inc.<\/strong> announced on <strong>September\u202f15,\u202f2025<\/strong> that it has formally submitted a <strong>Clinical Trial Application<\/strong> for its proprietary drug, <strong>RN3161<\/strong>, to the <strong>Human Research Ethics Committee (HREC)<\/strong> in Australia. The application marks a critical step toward initiating first\u2011in\u2011human studies of this next\u2011generation siRNA therapeutic.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-is-rn3161\">What Is RN3161?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GalNAc\u2011siRNA Platform<\/strong> \u2013 RN3161 is designed as a <strong>GalNAc\u2011conjugated siRNA<\/strong> that specifically targets the <strong>INHBE<\/strong> gene. The drug is built on Rona\u2019s proprietary <strong>GAIA platform<\/strong>, allowing precise delivery to hepatocytes and sustained gene silencing.<\/li>\n\n\n\n<li><strong>Unique Mechanism<\/strong> \u2013 By silencing <strong>INHBE<\/strong>, RN3161 reduces adipose tissue while sparing lean body mass\u2014a profile that sets it apart from current weight\u2011loss agents that often compromise muscle.<\/li>\n\n\n\n<li><strong>Long\u2011Lasting Effect<\/strong> \u2013 Preclinical data show that a single dose of RN3161 can maintain gene suppression for <strong>over 180 days<\/strong>, potentially enabling a dosing schedule of only <strong>once or twice per year<\/strong>. This reduced frequency could markedly improve patient adherence and overall treatment value.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-australia\">Why Australia?<\/h3>\n\n\n\n<p>Australia\u2019s robust regulatory framework and strong clinical research infrastructure make it an attractive initial market for early\u2011stage therapeutics. The HREC approval process is designed to safeguard participant safety while expediting development timelines, positioning RN3161 for a swift path to clinical validation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h3>\n\n\n\n<p>Upon HREC approval, Rona Therapeutics will initiate Phase\u202fI studies to evaluate safety, tolerability, and pharmacodynamics in healthy volunteers. Success in this pivotal trial could open the door to larger obesity and metabolic disorder programs, leveraging the drug\u2019s once\u2011a\u2011year dosing advantage to disrupt the current therapeutic landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai\u2011based Rona Therapeutics Inc. announced on September\u202f15,\u202f2025 that it has formally submitted a Clinical Trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41527,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[90,4354,64,498],"class_list":["post-41526","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug","tag-clinical-trial-filings","tag-nasdaq-rona","tag-rnai-aso","tag-rona-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai\u2011based Rona Therapeutics Inc. announced on September\u202f15,\u202f2025 that it has formally submitted a Clinical Trial Application for its proprietary drug, RN3161, to the Human Research Ethics Committee (HREC) in Australia. The application marks a critical step toward initiating first\u2011in\u2011human studies of this next\u2011generation siRNA therapeutic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41526\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application\" \/>\n<meta property=\"og:description\" content=\"Shanghai\u2011based Rona Therapeutics Inc. announced on September\u202f15,\u202f2025 that it has formally submitted a Clinical Trial Application for its proprietary drug, RN3161, to the Human Research Ethics Committee (HREC) in Australia. The application marks a critical step toward initiating first\u2011in\u2011human studies of this next\u2011generation siRNA therapeutic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41526\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T07:32:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-16T07:32:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application\",\"datePublished\":\"2025-09-16T07:32:47+00:00\",\"dateModified\":\"2025-09-16T07:32:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526\"},\"wordCount\":271,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1601.webp\",\"keywords\":[\"Clinical trial filings\",\"NASDAQ: RONA\",\"RNAi \\\/ ASO\",\"Rona Therapeutics\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41526#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41526\",\"name\":\"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1601.webp\",\"datePublished\":\"2025-09-16T07:32:47+00:00\",\"dateModified\":\"2025-09-16T07:32:48+00:00\",\"description\":\"Shanghai\u2011based Rona Therapeutics Inc. announced on September\u202f15,\u202f2025 that it has formally submitted a Clinical Trial Application for its proprietary drug, RN3161, to the Human Research Ethics Committee (HREC) in Australia. The application marks a critical step toward initiating first\u2011in\u2011human studies of this next\u2011generation siRNA therapeutic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41526\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41526#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai\u2011based Rona Therapeutics Inc. announced on September\u202f15,\u202f2025 that it has formally submitted a Clinical Trial Application for its proprietary drug, RN3161, to the Human Research Ethics Committee (HREC) in Australia. The application marks a critical step toward initiating first\u2011in\u2011human studies of this next\u2011generation siRNA therapeutic.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41526","og_locale":"en_US","og_type":"article","og_title":"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application","og_description":"Shanghai\u2011based Rona Therapeutics Inc. announced on September\u202f15,\u202f2025 that it has formally submitted a Clinical Trial Application for its proprietary drug, RN3161, to the Human Research Ethics Committee (HREC) in Australia. The application marks a critical step toward initiating first\u2011in\u2011human studies of this next\u2011generation siRNA therapeutic.","og_url":"https:\/\/flcube.com\/?p=41526","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-16T07:32:47+00:00","article_modified_time":"2025-09-16T07:32:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41526#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41526"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application","datePublished":"2025-09-16T07:32:47+00:00","dateModified":"2025-09-16T07:32:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41526"},"wordCount":271,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41526#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1601.webp","keywords":["Clinical trial filings","NASDAQ: RONA","RNAi \/ ASO","Rona Therapeutics"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41526#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41526","url":"https:\/\/flcube.com\/?p=41526","name":"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41526#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41526#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1601.webp","datePublished":"2025-09-16T07:32:47+00:00","dateModified":"2025-09-16T07:32:48+00:00","description":"Shanghai\u2011based Rona Therapeutics Inc. announced on September\u202f15,\u202f2025 that it has formally submitted a Clinical Trial Application for its proprietary drug, RN3161, to the Human Research Ethics Committee (HREC) in Australia. The application marks a critical step toward initiating first\u2011in\u2011human studies of this next\u2011generation siRNA therapeutic.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41526#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41526"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41526#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1601.webp","width":1080,"height":608,"caption":"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41526#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41526"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41526\/revisions"}],"predecessor-version":[{"id":41528,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41526\/revisions\/41528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41527"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}